Lord, Abbett & Co
CNST

Lord, Abbett & Co’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Lord, Abbett & Co’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,959,056
Closed -$45.8M – 732
2021
Q1 		$45.8M Buy
1,959,056
+277,100
+16% +$8.39M 0.12% 280
2020
Q4 		$48.4M Buy
1,681,956
+928,947
+123% +$23.4M 0.13% 250
2020
Q3 		$15.3M Buy
753,009
+46,024
+7% +$1.12M 0.05% 418
2020
Q2 		$21.2M Buy
+706,985
New +$25.5M 0.07% 358

Other funds holding CNST

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co's CNST Position: Q2 2021 in Review

Lord, Abbett & Co sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 1,959,056 shares — an estimated $45.8M sold.

Lord, Abbett & Co first reported a position in CNST in Q2 2020 and held it in 4 quarters. The position peaked at $48.4M in Q4 2020. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

  • Lord, Abbett & Co reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Lord, Abbett & Co sold 1,959,056 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $45.8M.
  • Lord, Abbett & Co first reported a position in Constellation Pharmaceuticals, Inc. in Q2 2020 and held it in 4 quarters.
  • Lord, Abbett & Co's Constellation Pharmaceuticals, Inc. position peaked at $48.4M in Q4 2020.
  • 153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Lord, Abbett & Co's 13F filing for Q2 2021, filed 11 Aug 2021.